113 related articles for article (PubMed ID: 15538115)
21. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
[TBL] [Abstract][Full Text] [Related]
24. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation.
Castro P; Roque L; Magalhães J; Sobrinho-Simões M
Int J Surg Pathol; 2005 Jul; 13(3):235-8. PubMed ID: 16086077
[TBL] [Abstract][Full Text] [Related]
25. Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy.
Finn SP; Smyth P; Cahill S; Streck C; O'Regan EM; Flavin R; Sherlock J; Howells D; Henfrey R; Cullen M; Toner M; Timon C; O'Leary JJ; Sheils OM
Virchows Arch; 2007 Mar; 450(3):249-60. PubMed ID: 17252232
[TBL] [Abstract][Full Text] [Related]
26. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Benassi MS; Ponticelli F; Azzoni E; Gamberi G; Pazzaglia L; Chiechi A; Conti A; Spessotto P; Scapolan M; Pignotti E; Bacchini P; Picci P
Histol Histopathol; 2007 Sep; 22(9):1017-24. PubMed ID: 17523079
[TBL] [Abstract][Full Text] [Related]
27. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract][Full Text] [Related]
28. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
29. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
30. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Pasini FS; Brentani MM; Kowalski LP; Federico MH
Head Neck; 2001 Sep; 23(9):725-32. PubMed ID: 11505481
[TBL] [Abstract][Full Text] [Related]
31. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
32. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.
Xu X; Quiros RM; Maxhimer JB; Jiang P; Marcinek R; Ain KB; Platt JL; Shen J; Gattuso P; Prinz RA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5968-79. PubMed ID: 14676122
[TBL] [Abstract][Full Text] [Related]
33. mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.
Lee HS; Park SY; Moon KC; Hong HK; Song CY; Hong SY
Histopathology; 2001 Aug; 39(2):203-9. PubMed ID: 11493338
[TBL] [Abstract][Full Text] [Related]
34. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
Ragno P; Montuori N; Covelli B; Hoyer-Hansen G; Rossi G
Cancer Res; 1998 Mar; 58(6):1315-9. PubMed ID: 9515821
[TBL] [Abstract][Full Text] [Related]
36. Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy.
Nelson KK; Gattuso P; Xu X; Prinz RA
Surgery; 2010 Oct; 148(4):654-60; discussion 660. PubMed ID: 20797751
[TBL] [Abstract][Full Text] [Related]
37. HLA-G is differentially expressed in thyroid tissues.
de Figueiredo Feitosa NL; Crispim JC; Zanetti BR; Magalhães PK; Soares CP; Soares EG; Neder L; Donadi EA; Maciel LM
Thyroid; 2014 Mar; 24(3):585-92. PubMed ID: 24089994
[TBL] [Abstract][Full Text] [Related]
38. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma.
Wagner PL; Moo TA; Arora N; Liu YF; Zarnegar R; Scognamiglio T; Fahey TJ
Ann Surg Oncol; 2008 Oct; 15(10):2833-41. PubMed ID: 18696160
[TBL] [Abstract][Full Text] [Related]
39. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
40. [Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
Qian J; Li B; Yin M; Shen P; Sun K
Zhonghua Er Ke Za Zhi; 2015 Jun; 53(6):453-8. PubMed ID: 26310557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
